Darrin Disley (L) and Pierre-Louis Joffrin
May 4, 2021 11:02 AM EDT
Financing

A UK-based start­up looks to beat Spark's Lux­tur­na at its own game with pro­gram­ma­ble cell plat­form for eye dis­ease

Nicole DeFeudis

Editor

Spark’s Lux­tur­na made waves in 2017 when it was ap­proved to treat in­her­it­ed reti­nal degra­da­tion by re­plac­ing the mu­tat­ed RPE65 gene with a nor­mal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

A service from the Financial Times